Kaiser Permanente Southern California Department of Research & Evaluation has developed a COVID-19 risk assessment factoring in a number of patient variables enabling a critical poor outcome without the need for any laboratory or diagnostic testing as reported in a recent press release by the California-headquartered health system. With the results of a retrospective study involving 26,600 emergency department patients suspected of COVID-19 infection, the study team recently had their results published in the peer-reviewed American Journal of Emergency Medicine. The Kaiser Permanente Southern California-developed assessment tool helps emergency department physicians better ensure patients get the right care, when they need it, by accurately predicting the probability that patients with COVID-19 symptoms will experience severe disease or even death. The tool produces a risk score which can be of particular value for physicians that need to make swift decisions at the point of emergency department care reports Adam Sharp, MD, emergency medicine physician and researcher.
Introduction to COVAS Score
Kaiser Permanente recently introduce the COVAS score as an assessment tool that incorporates a number of variables from comorbidities, obesity, vital signs, age and sex in their recent press release. Noteworthily, the major health system has already incorporated the COVAS too into the electronic health record system throughout Kaiser Permanente in Southern California, where it guides clinical decisions in emergency departments and urgent care centers.
Importance of this Kaiser-sponsored Study
Previous studies have focused on hospitalized patients, with little information about those treated outside of the inpatient setting. This particular work examines emergency department patients with suspected COVID-19 and provides helpful information to front-line physicians to inform care decisions, particularly during surges when hospital capacity can be limited.
The bottom line here reports Adam Sharp, MD, “As the pandemic surges again across the country and hospitalizations are increasing, front-line physicians often must make quick decisions to hospitalize or discharge patients with COVID-19 symptoms.” He went on, “We created a risk assessment that looks at many different patient variables that might predict a critical poor outcome—without any lab or diagnostic testing.”
The Retrospective Study
In a recent study, again the results of which were published in the American Journal of Emergency Medicine, the COVAS score accurately predicted the probability of death or the need for critical respiratory care within 7 days for patients seen at Kaiser Permanente emergency departments in Southern California.
Researchers conducted a retrospective study of 26,600 emergency department visits by adults for symptoms suspicious of COVID-19 at 15 Kaiser Permanente hospitals in Southern California between March 1, 2020 to April 30, 2020, a period of time when substantial community spread of COVID-19 was prevalent in the region but immediate COVID-19 test results were not.
The Study Results
The results inform front-line health professionals and health systems about which patients with COVID-19 symptoms, which include fever, cough, difficulty breathing, and fatigue, are at greatest risk of death or respiratory decompensation that would require ventilation or high-flow oxygen.
These valuable study results show the COVAS score “…particularly helpful to physicians in making these decisions at the time of the emergency department visit” reported Dr. Sharp. The Kaiser physician and researcher continued “I have used this tool successfully with my own patients in the emergency department and it helps provide necessary information to make informed decisions with patients.” He emphasized that the COVAS tool can “help to reassure low-risk patients, and alternatively can encourage those at high risk to receive hospital-based care that may speed their recovery.”
About Kaiser Permanente Southern California Department of Research & Evaluation
The Department of Research & Evaluation conducts high-quality, innovative research into disease etiology, prevention, treatment, and care delivery. Investigators conduct epidemiologic research, health services research, biostatistics research, and behavioral research as well as clinical trials. Major areas of study include chronic disease, infectious disease, cancer, drug safety and effectiveness, and maternal and child health. Headquartered in Pasadena, California, the department focuses on translating research to practice quickly to benefit the health and lives of Kaiser Permanente Southern California members and the general public. See more at kp.org/research.
About Kaiser Permanente
One of America’s largest healthcare systems, for 75 years, Kaiser Permanente has been committed to shaping the future of health and health care — and helping our members, patients, and communities experience more healthy years. We are recognized as one of America’s leading health care providers and not-for-profit health plans. Since July 21, 1945, Kaiser Permanente’s mission has been to provide high-quality, affordable health care services and to improve the health of our members and the communities we serve. We currently serve 12.4 million members in 8 states and the District of Columbia. Care for members and patients is focused on their total health and guided by their personal Permanente Medical Group physicians, specialists, and team of caregivers. Our expert and caring medical teams are empowered and supported by industry-leading technology advances and tools for health promotion, disease prevention, state-of-the-art care delivery, and world-class chronic disease management. Kaiser Permanente is dedicated to care
Adam L. Sharp, MD, MSC, Corresponding Author, Kaiser Permanente Department of Research & Evaluation
Call to Action: For physicians seeking in depth review, follow the link to the actual study results.